Skip to main content

Table 5 Cox regression model of multivariable analysis for overall survival and progression-free survival

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

  HR (95% CI) P value
Overall survival
 Cetuximab (yes vs. no) 1.457 (0.639 ~ 3.322) 0.371
 Smoking history (yes vs. no) 1.217 (0.537 ~ 2.757) 0.638
 Disease stage (IV vs. II–III) 5.052 (2.194 ~ 11.631) < 0.001
 EBVDNA (≥ vs. < 4000 copies) 2.072 (0.878 ~ 4.893) 0.096
 BMI (≥vs. < 23 kg/m2) 0.84 (0.373 ~ 1.893) 0.674
 CRP (≤ vs. >3.0 g/ml) 0.736 (0.267 ~ 2.027) 0.553
 VCA-IgA (< vs. ≥ 1:80) 0.877 (0.209 ~ 3.687) 0.858
 EA-IgA (< vs. ≥ 1:10) 0.894 (0.24 ~ 3.326) 0.867
 Family history of cancer (yes vs. no) 0.953 (0.271 ~ 3.346) 0.94
Progression-free survival
 Cetuximab (yes vs. no) 1.85 (0.956 ~ 3.58) 0.068
 Smoking history (yes vs. no) 0.917 (0.47 ~ 1.79) 0.8
 Disease stage (IV vs. II–III) 3.747 (1.823 ~ 7.704) < 0.001
 EBVDNA (≥ vs. < 4000 copies) 1.127 (0.571 ~ 2.222) 0.731
 BMI (≥vs. < 23 kg/m2) 0.802 (0.424 ~ 1.517) 0.497
 CRP (≤ vs. >3.0 g/ml) 1.315 (0.644 ~ 2.688) 0.452
 VCA-IgA (< vs. ≥ 1:80) 1.087 (0.376 ~ 3.143) 0.877
 EA-IgA (< vs. ≥ 1:10) 0.712 (0.268 ~ 1.892) 0.496
 Family history of cancer (yes vs. no) 0.678 (0.233 ~ 1.97) 0.302
  1. Abbreviations: EA early antigen, VCA viral capsid antigen, IgA immunoglobulin A, EBV DNA Epstein-Barr virus DNA, CRP C-reactive protein, BMI Body Mass Index